HOOKIPA to Participate in the Kempen Life Sciences Conference

Rhea-AI Summary

HOOKIPA Pharma, a clinical-stage biopharmaceutical company, announced participation in investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 20-21, 2022. The company focuses on developing immunotherapies using its proprietary arenavirus platform, targeting various cancers, including HPV16+ and KRAS-mutated cancers. HOOKIPA aims to advance novel treatments that enhance T cell responses and is also working on functional cures for HBV and HIV in collaboration with Gilead.

NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 - 21, 2022.

About HOOKIPA

HOOKIPA is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media Enquiries	Investors
Instinctif Partners	Matt Beck
hookipa@instinctif.com	Executive Director - Investor Relations
+44 (0)20 7457 2020	matthew.beck@hookipapharma.com +1 (917) 209-6886

FAQ

What event will HOOKIPA Pharma participate in April 2022?

HOOKIPA Pharma will participate in the Kempen Life Sciences Conference in Amsterdam on April 20-21, 2022.

What is HOOKIPA Pharma's focus in immunotherapy?

HOOKIPA Pharma focuses on developing novel immunotherapies based on their proprietary arenavirus platform, targeting serious diseases.

What types of cancers is HOOKIPA developing treatments for?

HOOKIPA is developing treatments for HPV16+ cancers, prostate cancer, and KRAS-mutated cancers.

Is HOOKIPA Pharma collaborating with any other company for treatments?

Yes, HOOKIPA is collaborating with Gilead to develop functional cures for HBV and HIV.

What stock exchange is HOOKIPA Pharma listed on?

HOOKIPA Pharma is listed on NASDAQ under the symbol 'HOOK'.